CoImmune company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

coimmune.com

Total Raised

$240.07M

Investors Count

45

Deal Terms

7

CoImmune Funding, CoImmune Valuation & CoImmune Revenue

20 Fundings

CoImmune's latest funding round was a Unattributed VC for $45M on November 10, 2020.

CoImmune's valuation in February 2019 was $11.1M.

CoImmune's latest post-money valuation is from February 2019.

Sign up for a free trial to see CoImmune's valuations in February 2014 and more.

CoImmune's 2013 revenue was $3.7M. CoImmune's most recent revenue is from 2013.

Sign up for a free trial to see revenue data from 2013 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/10/2020

Unattributed VC

$45M

0

FY undefined

7

2/13/2019

Acquired

$11.1M

0

FY undefined

4

4/23/2018

Take Private

Undisclosed Investors

0

FY undefined

2

2/7/2014

IPO

$99M

$99M

$3.7M

(38.21x)

FY 2013

10

11/21/2013

Series E - II

$99M

$0.00B

((9.99x))

FY 1234

10

Date

11/10/2020

2/13/2019

4/23/2018

2/7/2014

11/21/2013

Round

Unattributed VC

Acquired

Take Private

IPO

Series E - II

Amount

$45M

$99M

$99M

Investors

Undisclosed Investors

Valuation

$11.1M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

$3.7M

(38.21x)

FY 2013

$0.00B

((9.99x))

FY 1234

Sources

7

4

2

10

10

Financials

Income Statement

Income Statement

12/31/2021

12/31/2020

12/31/2019

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2021

12/31/2020

12/31/2019

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2021

12/31/2020

12/31/2019

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

CoImmune Deal Terms

7 Deal Terms

CoImmune's deal structure is available for 7 funding rounds, including their Acquired from February 13, 2019.

Round

Acquired

IPO

Series E

Series D

Series C

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

$99M

Dividend Rate

$99M

$99M

$99M

Liquidation Preferences

$99M

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Series E

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

CoImmune Investors

45 Investors

CoImmune has 45 investors. DSC Investment invested in CoImmune's Unattributed VC funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

11/10/2020

11/10/2020

1
Unattributed VC

Venture Capital

South Korea

11/10/2020

11/10/2020

1
Unattributed VC

Angel Investor (Individual)

Italy

11/10/2020

11/10/2020

1
Unattributed VC

Venture Capital

South Korea

00/00/0000

00/00/0000

Magna Investment

Subscribe to see more

Venture Capital

South Korea

00/00/0000

00/00/0000

Brain Asset Management

Subscribe to see more

Asset/Investment Management

South Korea

First funding

11/10/2020

11/10/2020

11/10/2020

00/00/0000

00/00/0000

Last Funding

11/10/2020

11/10/2020

11/10/2020

00/00/0000

00/00/0000

Investor

Magna Investment

Brain Asset Management

Rounds

1
Unattributed VC
1
Unattributed VC
1
Unattributed VC

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Angel Investor (Individual)

Venture Capital

Venture Capital

Asset/Investment Management

Location

South Korea

Italy

South Korea

South Korea

South Korea

CoImmune Acquisitions

1 Acquisition

CoImmune acquired 1 company. Their latest acquisition was Formula Pharmaceuticals on January 17, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/17/2020

Other

$99M

Acquired

4

Date

1/17/2020

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

4

You May Also Like

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

I
ImmuRx

ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

J
JadoLabs

JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.